Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Randomized phase III trial to determine the effectiveness of High dose versus Standard dose of Vitamin D2 (Ergocalciferol) given with Docetaxel in patients with metastatic breast cancer
2 Arms Randomization in patients with metastatic breast cancer.
Arm A = Docetaxel + High dose Vitamin D2
Arm B = Docetaxel + Standard dose Vitamin D2
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Arm A | Experimental | Arm A = Docetaxel + High dose Vitamin D2 |
|
| Arm B | Active Comparator | Docetaxel + Standard dose Vitamin D2 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Docetaxel + High dose Vitamin D2 | Drug | Docetaxel + High dose Vitamin D2 |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Time to progression is from the start of Docetaxel to disease progression. Patients who have not progressed at the time of study completion or who are lost to follow-up are censored at the last Vitamin D administration date. | 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Overall survival is defined as the time from start of Docetaxel to death due to any cause. Patients for whom no death is captured on the clinical database are censored at the last date they were known to be alive. | 1 year |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Pregnant or lactating women.
Male breast cancer.
Women of childbearing potential unless surgically sterile or using adequate measures of contraception.
Metastatic inflammatory breast cancer.
CNS metastasis.
Leptomeningeal carcinomatosis.
Malignant hypercalcemia.
History of kidney stones.
History of active primary hyperparathyroidism.
Normal 25 (OH) Vitamin D level ≥100 nmol/L or ≥ 40 ng/L.
Previous or concomitant malignancy of any type, except adequately treated basal cell carcinoma of the skin or in situ cervix cancer.
Patient on any anti-Psychotic medications or Steroid therapy.
History of malabsorption syndrome (pancreatic insufficiency, celiac disease and tropical sprue).
Any of the following abnormal baseline hematological values:
Any of the following abnormal laboratory tests: total serum bilirubin >2.00 x ULN (upper limit of normal), AST, ALT > 2.5 x ULN or ALP >2.50 x ULN (upper limit of normal).
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Taher Tweigeri, MD | Contact | 0096614647272 | 38047 | ttwegieri@kfshrc.edu.sa |
| Romelia Retuta | Contact | 966-1-4647272 | 32957 | romelia@kfshrc.edu.sa |
| Name | Affiliation | Role |
|---|---|---|
| Taher Al-Tweigeri, MD | KFSHRC | Principal Investigator |
| Dahish Ajarim, MD | KFSHRC | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Kuwait Cancer Center | Not yet recruiting | Kuwait City | Kuwait | |||
| King Faisal Specialist Hospital & Research Center |
Not provided
Not provided
Not provided
Not provided
Not provided
| Docetaxel + Standard dose Vitamin D2 |
| Drug |
Docetaxel + Standard dose Vitamin D2 |
|
| Recruiting |
| Riyadh |
| Central |
| 11211 |
| Saudi Arabia |
|
| King Abdulaziz Hospital and Oncology Center | Not yet recruiting | Jeddah | Saudi Arabia |
|
| King Abdulaziz Medical City | Not yet recruiting | Riyadh | Saudi Arabia |
| King Fahad Medical City | Not yet recruiting | Riyadh | Saudi Arabia |
| Tawam Hospital | Not yet recruiting | Al Ain City | United Arab Emirates |
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077143 | Docetaxel |
| D004872 | Ergocalciferols |
| ID | Term |
|---|---|
| D043823 | Taxoids |
| D043822 | Cyclodecanes |
| D003516 | Cycloparaffins |
| D006840 | Hydrocarbons, Alicyclic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
| D004224 | Diterpenes |
| D013729 | Terpenes |
| D002782 | Cholestenes |
| D002776 | Cholestanes |
| D013256 | Steroids |
| D000072473 | Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |
| D013261 | Sterols |
| D014807 | Vitamin D |
| D012632 | Secosteroids |
| D008563 | Membrane Lipids |
| D008055 | Lipids |
Not provided
Not provided